Biotech Industry Experiencing More FDA New Drug Approvals in 2012

Five Star Equities Provides Stock Research on ImmunoCellular Therapeutics and Zalicus


NEW YORK, NY -- (Marketwire) -- 11/19/12 -- The Biotech Industry has skyrocketed in 2012 as an increase in the number of new drug approvals has boosted investor optimism within the industry. The iShares Nasdaq Biotechnology Index Fund (IBB) and the SPDR S&P Biotech ETF (XBI) have both gained over 25 percent year-to-date. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on ImmunoCellular Therapeutics Ltd. (NYSE: IMUC) and Zalicus Inc. (NASDAQ: ZLCS).

Access to the full company reports can be found at:
www.FiveStarEquities.com/IMUC
www.FiveStarEquities.com/ZLCS

"In 2011, the U.S. FDA approved 30 new drugs, compared to 21 in 2010," S&P Capital IQ wrote in a note. "Through September 2012, the year-to-date total was 22. We see an improving trend for FDA first cycle review approvals and a rise in the rate of new drug approvals for rare diseases, which we think is helping to boost investor sentiment for the agency, after years of criticism stemming from inconsistency in making and communicating its decisions."

Another key factor in the Biotech Industry's success has been the "patent cliff" major pharmaceuticals have faced in 2012. Major drug manufacturers have looked to biotech companies to help offset major revenue losses from expiring patents as it is less time consuming than developing new drugs through R&D.

Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

ImmunoCellular Therapeutics' technologies have potential applications in many cancers with high unmet medical need, including pancreatic, ovarian, colon, small-cell lung, and multiple myeloma. The company's ICT-107 cancer vaccine is anticipated to complete a Phase IIb trial at the end of 2013.

Zalicus is focused on the discovery and development of innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease. The company's inflammatory drug Z944, assuming it successfully completes its Phase 1 MAD study, could enter Phase 2 clinical development in the first quarter of 2013.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
www.FiveStarEquities.com/disclaimer

Add to DiggBookmark with del.icio.usAdd to Newsvine

Contact:
Five Star Equities
Email Contact